plague vaccine

Summary

Summary: A suspension of killed Yersinia pestis used for immunizing people in enzootic plague areas.

Top Publications

  1. ncbi Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery
    Vinita Tripathi
    Department of Biochemistry, All India Institute of Medical Sciences AIIMS, Ansari Nagar, New Delhi 110029, India
    Vaccine 24:3279-89. 2006
  2. pmc Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates
    Steven B Mizel
    Department of Microbiology and Immunology, Wake Forest University School of Medicine, Medical Center Blvd, Winston Salem, NC 27157 1064, USA
    Clin Vaccine Immunol 16:21-8. 2009
  3. pmc Human immune response to a plague vaccine comprising recombinant F1 and V antigens
    E D Williamson
    Dstl Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom
    Infect Immun 73:3598-608. 2005
  4. pmc Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines
    Lauriane E Quenee
    Department of Microbiology, University of Chicago, 920 East 58th Street, Chicago, IL 60637, USA
    Vaccine 29:6572-83. 2011
  5. ncbi Prospects for new plague vaccines
    Valentina A Feodorova
    Scientific and Research Institute for Medical and Veterinary Biotechnologies, Russia Switzerland, Branch in Saratov, 9 Proviantskaya Street, Box 1580, Saratov 410028, Russia
    Expert Rev Vaccines 8:1721-38. 2009
  6. pmc Immunogenicity of a Yersinia pestis vaccine antigen monomerized by circular permutation
    David A Chalton
    Institute for Cell and Molecular Biosciences, University of Newcastle upon Tyne, Framlington Place, Newcastle NE2 4HH, United Kingdom
    Infect Immun 74:6624-31. 2006
  7. ncbi Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response
    Sara W Montminy
    Division of Infectious Diseases and Immunolbin/l.pl?link=puid_16980981">ncbi Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide reogy, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
    Nat Immunol 7:1066-73. 2006
  8. ncbi Progress on plague vaccine development
    Jason A Rosenzweig
    Department of Biology, Center for Bionanotechnology and Environmental Research CBER, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA
    Appl Microbiol Biotechnol 91:265-86. 2011
  9. ncbi CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague
    Kei Amemiya
    Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702, United States
    Vaccine 27:2220-9. 2009
  10. ncbi Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen
    Maria J Chiuchiolo
    Department of Genetic Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Infect Dis 194:1249-57. 2006

Scientific Experts

Detail Information

Publications143 found, 100 shown here

  1. ncbi Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery
    Vinita Tripathi
    Department of Biochemistry, All India Institute of Medical Sciences AIIMS, Ansari Nagar, New Delhi 110029, India
    Vaccine 24:3279-89. 2006
    ..There is a need for an improved plague vaccine that may overcome the limitation of presently available whole cell vaccine...
  2. pmc Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates
    Steven B Mizel
    Department of Microbiology and Immunology, Wake Forest University School of Medicine, Medical Center Blvd, Winston Salem, NC 27157 1064, USA
    Clin Vaccine Immunol 16:21-8. 2009
    ..On the basis of our results, we believe that flagellin-F1-V is an outstanding candidate for evaluation in studies with humans...
  3. pmc Human immune response to a plague vaccine comprising recombinant F1 and V antigens
    E D Williamson
    Dstl Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom
    Infect Immun 73:3598-608. 2005
    The human immune response to a new recombinant plague vaccine, comprising recombinant F1 (rF1) and rV antigens, has been assessed during a phase 1 safety and immunogenicity trial in healthy volunteers...
  4. pmc Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines
    Lauriane E Quenee
    Department of Microbiology, University of Chicago, 920 East 58th Street, Chicago, IL 60637, USA
    Vaccine 29:6572-83. 2011
    ..A US Food and Drug Administration (FDA)-licensed plague vaccine is currently not available. Vaccine developers have focused on two subunits of Y...
  5. ncbi Prospects for new plague vaccines
    Valentina A Feodorova
    Scientific and Research Institute for Medical and Veterinary Biotechnologies, Russia Switzerland, Branch in Saratov, 9 Proviantskaya Street, Box 1580, Saratov 410028, Russia
    Expert Rev Vaccines 8:1721-38. 2009
    ..The regulatory problems inherent in licensing vaccines for which efficacy data are unavailable and their possible solutions are discussed herein...
  6. pmc Immunogenicity of a Yersinia pestis vaccine antigen monomerized by circular permutation
    David A Chalton
    Institute for Cell and Molecular Biosciences, University of Newcastle upon Tyne, Framlington Place, Newcastle NE2 4HH, United Kingdom
    Infect Immun 74:6624-31. 2006
    ..The use of circular permutation in vaccine design has not been reported previously...
  7. ncbi Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response
    Sara W Montminy
    Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
    Nat Immunol 7:1066-73. 2006
    ..pestis virulence. Evading TLR4 activation by lipid A alteration may contribute to the virulence of various Gram-negative bacteria...
  8. ncbi Progress on plague vaccine development
    Jason A Rosenzweig
    Department of Biology, Center for Bionanotechnology and Environmental Research CBER, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA
    Appl Microbiol Biotechnol 91:265-86. 2011
    ..This review article will describe the current vaccine candidates being evaluated in various model systems and provide an overall summary on the progress of this important endeavor...
  9. ncbi CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague
    Kei Amemiya
    Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702, United States
    Vaccine 27:2220-9. 2009
    The current U.S. Department of Defense candidate plague vaccine is a fusion between two Yersinia pestis proteins: the F1 capsular protein, and the low calcium response (Lcr) V-protein...
  10. ncbi Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen
    Maria J Chiuchiolo
    Department of Genetic Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Infect Dis 194:1249-57. 2006
    ..These observations suggest that an Ad gene-transfer vector expressing V antigen is a candidate for development of an effective anti-plague vaccine.
  11. ncbi Plague vaccines and the molecular basis of immunity against Yersinia pestis
    Lauriane E Quenee
    Department of Microbiology, University of Chicago, Chicago, IL, USA
    Hum Vaccin 5:817-23. 2009
    ..Several subunit vaccines, for example rF1+rV (rYP002), rF1V or rV10, are being developed to generate plague protection in humans. Efficacy testing and licensure for human use requires the establishment of correlates for plague immunity...
  12. pmc Current challenges in the development of vaccines for pneumonic plague
    Stephen T Smiley
    Trudeau Institute, 154 Algonquin Avenue, Saranac Lake, NY 12983, USA
    Expert Rev Vaccines 7:209-21. 2008
    ..Extensively antibiotic-resistant Y. pestis strains exist and we currently lack a safe and effective pneumonic plague vaccine. These facts raise concern that Y. pestis may be exploited as a bioweapon...
  13. ncbi A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague
    Shixia Wang
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605, USA
    Vaccine 22:3348-57. 2004
    ..These results support that optimized DNA vaccines have the potential to protect against bacterial pathogens than is generally recognized...
  14. ncbi A baiting system for delivery of an oral plague vaccine to black-tailed prairie dogs
    Terry E Creekmore
    U S Geological Service, National Wildlife Health Center, 6006 Schroeder Road, Madison, Wisconsin 53711, USA
    J Wildl Dis 38:32-9. 2002
    ..October 1999 to identify bait preference, biomarker efficacy, and bait acceptance rates for delivering an oral plague vaccine to black-tailed prairie dogs (Cynomys ludovicianus)...
  15. ncbi Purification and characterization of a recombinant Yersinia pestis V-F1 "Reversed" fusion protein for use as a new subunit vaccine against plague
    Jeremy L Goodin
    Bacteriology Division, U S Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA
    Protein Expr Purif 76:136-44. 2011
    ..F1S-V-F1 polymerization characteristics were comparable to the native F1. The purified F1S-V-F1 protein appeared equivalent to F1-V in its ability to be recognized by neutralizing antibodies...
  16. ncbi Immunisation against plague by transcutaneous and intradermal application of subunit antigens
    J E Eyles
    Biomedical Sciences, Dstl, Porton Down, Salisbury, Wiltshire SP4 0JQ, UK
    Vaccine 22:4365-73. 2004
    ..These data suggest that transcutaneous immunisation may be a simple and non-invasive method for immunising individuals against plague...
  17. pmc Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice
    Joseph N Brewoo
    Inviragen, Inc, Madison, WI 53719, USA
    Vaccine 28:5891-9. 2010
    ..Based on their safety and efficacy in mice, these MVA/Y. pestis recombinants are candidates for further development as biodefense and public health vaccines...
  18. pmc Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague
    Jeremy L Goodin
    Bacteriology Division, U S Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA
    Protein Expr Purif 53:63-79. 2007
    ..pestis CO92. Thus, vaccination with F1-V monomer and multimeric forms resulted in significant, and essentially equivalent, protection...
  19. ncbi The natural history and incidence of Yersinia pestis and prospects for vaccination
    E D Williamson
    Biomedical Sciences, Dstl Porton Down, Salisbury SP4 0JQ, UK
    J Med Microbiol 61:911-8. 2012
    ..The considerable challenges in achieving a vaccine which is licensed for human use and which will comprehensively protect against this serious human pathogen are assessed...
  20. ncbi Sylvatic plague vaccine: a new tool for conservation of threatened and endangered species?
    Rachel C Abbott
    US Geological Survey, National Wildlife Health Center, Madison, WI 53711, USA
    Ecohealth 9:243-50. 20alt="ncbi"> Sylvatic plague vaccine: a new tool for conservation of thr12
    ..strategy would be similarly enhanced with the addition of a cost-effective, bait-delivered, sylvatic plague vaccine for prairie dogs...
  21. pmc Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols
    Richard J Thomas
    Defence Science and Technology Laboratory Dstl, Porton Down, Salisbury, Wiltshire SP40JQ, United Kingdom
    Infect Immun 77:1315-23. 2009
    ..Although there were major differences in pathogenesis, the recombinant F1 and V antigen vaccine and ciprofloxacin protected against plague infections caused by small- and large-particle aerosols...
  22. pmc Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine
    Tatiana E Erova
    Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA
    Clin Vaccine Immunol 20:227-38. 2013
    ..Together, the addition of Y. pestis outer membrane proteins to a new-generation recombinant vaccine could provide protection against a wide variety of Y. pestis strains...
  23. ncbi Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V)
    Patricia Fellows
    DynPort Vaccine Company, A CSC Company, 64 Thomas Johnson Drive, Frederick, MD 21702, United States
    Vaccine 28:7748-56. 2010
    ..evaluate the ability of antibodies generated in cynomolgus macaques and humans vaccinated with a recombinant plague vaccine (rF1V) to protect naïve Swiss Webster mice against pneumonic plague...
  24. ncbi Plague
    E D Williamson
    Defence Science and Technology Laboratory Dstl, Porton Down, Salisbury, Wilts SP4 0JQ, UK
    Vaccine 27:D56-60. 2009
    ..This paper reviews the progress towards an improved vaccine for plague and assesses the likely impact of a prophylactic vaccine for bubonic and pneumonic plague...
  25. pmc IL-17 contributes to wards an improved vaccine for plague and assescell-mediated defense against pulmonary Yersinia pestis infection
    Jr Shiuan Lin
    Trudeau Institute, Saranac Lake, NY 12983, USA
    J Immunol 186:1675-84. 2011
    ..pestis challenge, and we suggest that pneumonic plague vaccines should aim to induce mixed type 1 and type 17 cellular responses...
  26. pmc An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model
    E D Williamson
    DERA, Chemical and Biological Defence Sector, Salisbury, UK
    Clin Exp Immunol 116:107-14. 1999
    ..05) with protection. The titres of IgG1 in vaccinated mice which correlated with 90%, 50% and 10% protection have been determined and provide a useful model to predict vaccine efficacy in man...
  27. pmc Yersinia pestis CO92 delta yopH is a potent live, attenuated plague vaccine
    Sarah S Bubeck
    Department of Microbiology and Immunology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229, USA
    Clin Vaccine Immunol 14:1235-8. 2007
    ..When it is used as a live, attenuated vaccine, CO92 delta yopH provides a high degree of protection from parental and respiratory challenge with Y. pestis CO92...
  28. ncbi The anti-plague system and the Soviet biological warfare program
    Raymond A Zilinskas
    Monterey Institute of International Studies, Center for Nonproliferation Studies, Monterey, California 93940, USA
    Crit Rev Microbiol 32:47-64. 2006
    ..This article describes the anti-plague system's activities relevant to both aspects of the Soviet Union's biological warfare program, offense and defense, and analyzes its contributions to each...
  29. ncbi N255 is a key residue for recognition by a monoclonal antibody which protects against Yersinia pestis infection
    Jim Hill
    Defence Science and Technology Laboratory, Porton Down, Salisbury, Wiltshire SP4 0JQ, UK
    Vaccine 27:7073-9. 2009
    ..3 protects by binding to LcrV(Ype) and interfering with protein-protein interactions necessary for type three secretion...
  30. pmc Vaccination with liverpt">..3 protects by binding to LcrV(Ype) and Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection
    Alexander V Philipovskiy
    Trudeau Institute, 154 Algonquin Avenue, Saranac Lake, NY 12983, USA
    Infect Immun 75:878-85. 2007
    ..To aid the development of a safe and effective plague vaccine, we are investigating roles for T cells during defense against Y. pestis infection...
  31. pmc Yersinia pestis caf1 variants and the limits of plague vaccine protection
    Lauriane E Quenee
    Department of Microbiology, University of Chicago, Chicago, Illinois 60637, USA
    Infect Immun 76:2025-36. 2008
    ....
  32. ncbi Protective efficacy of a fully recombinant plague vaccine in the guinea pig
    S M Jones
    Defence Science and Technology Laboratory, Porton Down, Salisbury, Wiltshire SP4 0JQ, UK
    Vaccine 21:3912-8. 2003
    ..Cross-protection of the mouse with guinea pig IgG suggests that the recognition of neutralising epitopes in the F1 and V proteins is conserved between these two species...
  33. pmc Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells
    Yoonkyung Do
    Laboratory of Cellular Physiology and Immunology and Chris Browne Center for Immunology and Immune Diseases, The Rockefeller University, New York 10065 6399, USA
    Eur J Immunol 38:20-9. 2008
    ..This study sets the stage for the analysis of functional roles of IFN-gamma-producing T cells in Y. pestis infection...
  34. ncbi Vaccination against bubonic and pneumonic plague
    R W Titball
    Defence Evaluation and Research Agency, CBD Porton Down, Salisbury, SP4 0JQ, Wilts, UK
    Vaccine 19:4175-84. 2001
    ..A killed whole cell plague vaccine has been used in the past, but recent studies in animals have shown that this vaccine offers poor protection ..
  35. pmc Immune defense against pneumonic plague
    Stephen T Smiley
    Trudeau Institute, Saranac Lake, NY 12983, USA
    Immunol Rev 225:256-71. 2008
    ..Here, I review the immunology of pneumonic plague, focusing on evidence that humoral and cellular defense mechanisms collaborate to defend against pulmonary Y. pestis infection...
  36. pmc Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague
    Claire A Cornelius
    Department of Microbiology, University of Chicago, Chicago, Illinois 60637, USA
    Infect Immun 76:5588-97. 2008
    ....
  37. pmc Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine
    Christina L Airhart
    Department of Microbiology, Molecular Biology, and Biochemistry, University of Idaho, 142 Life Science, Moscow, ID 83844 3052, United States
    Vaccine 26:5554-61. 2008
    ..This intranasal vaccine showed 90% protection in Sprague-Dawley rats challenged with 1000 LD50. We conclude that lipid A mimetics are highly effective adjuvants for an i.n. plague vaccine.
  38. pmc Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection
    Anasuya Chattopadhyay
    Department of Pathology, Yale University School of Medicine, 310 Cedar Street LH 315, New Haven, CT 06510, USA
    Vaccine 26:6329-37. 2008
    We have developed an experimental recombinant vesicular stomatitis virus (VSV) vectored plague vaccine expressing a secreted form of Yersinia pestis low calcium response protein V (LcrV) from the first position of the VSV genome...
  39. pmc Generation of Yersinia pestis attenuated strains by signature-tagged mutagenesis in search of novel vaccine candidates
    Yehuda Flashner
    Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona, 74100, Israel
    Infect Immun 72:908-15. 2004
    ..This Kimberley53pcm mutant was superior to the EV76 live vaccine strain because it induced 10- to 100-fold-higher antibody titers to the protective V and F1 antigens and because it conferred efficacious protective immunity...
  40. pmc Clinical and pathologic features of cynomolgus macaques (Macaca fascicularis) infected with aerosolized Yersinia pestis
    Roger Van Andel
    Lovelace Respiratory Research Institute, Albuquerque, NM, USA
    Comp Med 58:68-75. 2008
    ....
  41. ncbi Comparison of immunological responses of plague vaccines F1+rV270 and EV76 in Chinese-origin rhesus macaque, Macaca mulatta
    Y Qiu
    Laboratory of Analytical Microbiology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
    Scand J Immunol 72:425-33. 2010
    ..pestis challenge by subcutaneous route in Chinese-origin rhesus macaques...
  42. ncbi Humoral immune responses and protective efficacy of sequential B- and T-cell epitopes of V antigen of Yersinia pestis by intranasal immunization in microparticles
    Jayaprakash Babu Uppada
    Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
    Med Microbiol Immunol 198:247-56. 2009
    ....
  43. pmc Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis
    G W Anderson
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702 5011, USA
    Infect Immun 64:4580-5. 1996
    ..This work demonstrates that a subunit plague vaccine formulated for human use provides significant protection against bubonic plague caused by an F1- strain (C12) ..
  44. pmc Amino acid residues 196-225 of LcrV represent a plague protective epitope
    Lauriane E Quenee
    Department of Microbiology, University of Chicago, 920 East 58th Street, Chicago, IL 60637, USA
    Vaccine 28:1870-6. 2010
    ..These results identify LcrV residues 196-225 as a linear epitope that is recognized by the murine immune system to confer plague protection...
  45. pmc Cell-mediated protection against pulmonary Yersinia pestis infection
    Michelle A Parent
    Trudeau Institute, 154 Algonquin Avenue, Saranac Lake, NY 12983, USA
    Infect Immun 73:7304-10. 2005
    ..These findings establish that vaccine-primed cellular immunity can protect against pulmonary Y. pestis infection and suggest that vaccines promoting both humoral and cellular immunity will most effectively combat pneumonic plague...
  46. ncbi Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense
    T V Inglesby
    Center for Civilian Biodefense Studies, Johns Hopkins University Schools of Medicine, Baltimore, MD 21202, USA
    JAMA 283:2281-90. 2000
    ..The Working Group on Civilian Biodefense has developed consensus-based recommendations for measures to be taken by medical and public health professionals following the use of plague as a biological weapon against a civilian population...
  47. ncbi Defining the genome content of live plague vaccines by use of whole-genome DNA microarray
    Dongsheng Zhou
    Laboratory of Analytical Microbiology, National Center for Biomedical Analysis, Army Center for Microbial Detection and Research, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences AMMS, Beijing 100071, PR China
    Vaccine 22:3367-74. 2004
    ..The whole-genome DNA microarray also provides an ideal tool to perform the pre-evaluation of a vaccine strain for its high throughput to determine the genomic features essential or unallowable for the live vaccines...
  48. ncbi Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates
    E D Williamson
    Defence Science and Technology Laboratory, Porton Down, Salisbury, Wilts UK SP4 0JQ, UK
    Microb Pathog 42:11-21. 2007
    ..Serum samples from representative macaques within this time period also inhibited the Yersinia-mediated cytotoxicity of J774 macrophages in a qualitative in vitro assay of type three secretion...
  49. ncbi Sequential proteolytic processing of the capsular Caf1 antigen of Yersinia pestis for major histocompatibility complex class II-restricted presentation to T lymphocytes
    Julie A Musson
    Musculoskeletal Research Group, Institute of Cellular Medicine, University of Newcastle, Framlington Place, Newcastle upon Tyne NE2 4HH, United Kingdom
    J Biol Chem 281:26129-35. 2006
    Julie A Musson
    Musculoskeletal Research Group, Institute of Cellular Medicine, University of Newcastle, Framlington Place, Newcastle upon Tyne NE2ss="excerpt">....
  50. ncbi Effect of homologous and heterologous prime-boost on the immune response to recombinant plague antigens
    Audrey Glynn
    Department of Microbiology and Immunology, Program in Molecular Pathogenesis and Immunity, 1430 Tulane Avenue, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Vaccine 23:1957-65. 2005
    ..These studies provide important insights into the development of new-generation biodefense vaccines...
  51. ncbi A plant-produced plague vaccine candidate confers protection to monkeys
    Vadim Mett
    Fraunhofer USA Center for Molecular Biotechnology, 9 Innovation Way, Suite 200, Newark, DE 19711, USA
    Vaccine 25:3014-7. 2007
    ..pestis. This study clearly demonstrates the efficacy of a plant-produced plague vaccine candidate in a primate model.
  52. ncbi Comparison of mouse, guinea pig and rabbit models for evaluation of plague subunit vaccine F1+rV270
    Zhizhen Qi
    Qinghai Institute for Endemic Disease Prevention and Control of Qinghai Province, Xining 811602, China
    Vaccine 28:1655-60. 2010
    ..The subunit vaccine and EV76 vaccine are able to provide protection for animals against Y. pestis challenge, but the subunit vaccines have obvious advantages over EV76 in terms of safety of use...
  53. ncbi Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague
    Helen S Garmory
    Dstl Chemical and Biological Sciences, Porton Down, Salisbury SP4 0JQ, UK
    Vaccine 21:3051-7. 2003
    ..pestis V antigen as a candidate oral plague vaccine. SL3261 was transformed with the expression plasmid pTrc-LcrV, containing the lcrV gene encoding V antigen...
  54. ncbi Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection
    Taff Jones
    ID Biomedical Corporation of Quebec, 525 Cartier Blvd West, Laval, Montreal, Que, Canada H7V 3S8
    Vaccine 24:1625-32. 2006
    ..Mice immunized in against lethal aerosolized plague infection
  55. pmc Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV
    Kristin L Debord
    Department of Microbiology, University of Chicago, 920 E 58th Street, Chicago, Illinois 60637, USA
    Infect Immun 74:4910-4. 2006
    ..Immunization with rV10 generates robust antibody responses that protect mice against bubonic plague and pneumonic plague, suggesting that rV10 may serve as an improved plague vaccine.
  56. pmc Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection
    Michelle A Parent
    Trudeau Institute, 154 Algonquin Avenue, Saranac Lake, NY 12983, USA
    Infect Immun 74:3381-6. 2006
    ..pestis challenge. These observations strongly suggest that plague vaccines should striss="ol_sub">Michelle A Parent
    Trudeau Institute, 154 Algonquin Avenue, Saranac Lake, NY 12983, USA
    Infect Immun 74:3381-6. 2006
  57. ncbi Vaccination with F1-V fusion protein protects black-footed ferrets (Mustela nigripes) against plague upon oral challenge with Yersinia pestis
    Tonie E Rocke
    US Geological Survey, National Wildlife Health Center, 6006 Schroeder Road, Madison, WI 53711, USA
    J Wildl Dis 44:1-7. 2008
    ..High titers to both F1 and V (mean reciprocal titers of 18,552 and 99,862, respectively) were found in all vaccinates up to 2 yr postvaccination, whereas seven control animals remained antibody negative throughout the same time period...
  58. ncbi Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity
    Jim E Eyles
    Biomedical Sciences Department, Dstl, Porton Down, Wiltshire SP4 0JQ, UK
    Vaccine 25:7301-6. 2007
    ..pestis: intradermal injection might therefore be considered as a potential minimally invasive method of plague vaccine administration. These data have implications for the design of therapeutic strategies against plague infection.
  59. ncbi A Yersinia pestis lpxM-mutant live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs
    V A Feodorova
    Russian State Anti Plague Research Institute Microbe, 46 Universitetskaya Street, Saratov 410005, Russia
    Vaccine 25:7620-8. 2007
    ..5 x 10(4) CFU) of this vaccine. A subcutaneous challenge with 2000 median lethal doses (equal to 20,000 CFU) of fully virulent Y. pestis 231 strain, is a 6-10-fold higher dose than that which the EV NIIEG itself can protect against...
  60. ncbi Cell-mediated defense against Yersinia pestis infection
    Stephen T Smiley
    Trudeau Institute, Saranac Lake, NY, USA
    Adv Exp Med Biol 603:376-86. 2007
    ..To counter that possibility, it is essential that we develop a safe and effective pneumonic plague vaccine. Recent studies suggest that the leading vaccine candidate, which primarily stimulates antibody-mediated ..
  61. ncbi Oral vaccination with different antigens from Yersinia pestis KIM delivered by live attenuated Salmonella typhimurium elicits a protective immune response against plague
    Christine G Branger
    Center for Infectious Diseases and Vaccinology, The Biodesign Institute, Arizona State University, Tempe, USA
    Adv Exp Med Biol 603:387-99. 2007
    ..This finding should facilitate the design and development of a new generation of vaccines against Y. pestis...
  62. ncbi Yersinia pestis YadC: a novel vaccine candidate against plague
    Brian S Murphy
    Department of Internal Medicine, University of Kentucky, Lexington, USA
    Adv Exp Med Biol 603:400-14. 2007
    ..This mixed Thl/Th2 response suggests that YadC's protection may involve a different adaptive immune response than the LcrV protein that currently is part of plague vaccines...
  63. ncbi Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague
    E D Williamson
    Dstl Porton Down, Salisbury, Wilts SP4 0JQ, UK
    Vaccine 25:1142-8. 2007
    ....
  64. pmc Vaccination of mice with a Yop translocon complex elicits antibodies that are protective against infection with F1- Yersinia pestis
    Maya I Ivanov
    Center for Infectious Diseases, SUNY Stony Brook, Stony Brook, NY 11794 5222, USA
    Infect Immun 76:5181-90. 2008
    ..pestis. These results indicate that anti-translocon antibodies can be used as immunotherapy to treat infections by F1(-) Y. pestis...
  65. pmc A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague
    Hitoki Yamanaka
    Veterinary Molecular Biology, Montana State University, Bozeman, Montana 59717 3610, USA
    Infect Immun 76:4564-73. 2008
    ..These results show that IL-12 can be used as a molecular adjuvant to enhance protective immunity against pneumonic plague, but in a dose-dependent fashion...
  66. ncbi [Prophylactic use of ceftriaxone in combination with F I antigen immunization in studies on uninbred albino mice infected by Yersinia pestis. Antiplague immunity development]
    I V Ryzhko
    Antibiot Khimioter 51:8-12. 2006
    ..pestis EV NIIEG (II 1.2x10(5)). The results of the study are indicative of the prospective use of subsingle vaccines of the new generation based on F I antigen for combined specific and urgent prophylaxis...
  67. pmc Relative immunogenicity and protection potential of candidate Yersinia Pestis antigens against lethal mucosal plague challenge in Balb/C mice
    Shixia Wang
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605 2397, USA
    Vaccine 26:1664-74. 2008
    ..These results demonstrate that DNA immunization is effective in screening, optimizing and comparing optimal antigen designs and immunogenicity of candidate antigens for the development of a subunit-based plague vaccine.
  68. ncbi Protective immunity against plague
    Claire Cornelius
    Department of Microbiology, University of Chicago, IL, USA
    Adv Exp Med Biol 603:415-24. 2007
    ..More research is required to examine the molecular mechanisms of vaccine protection affo class="ol_sub">Claire Cornelius
    Department of Microbiology, University of Chicago, IL, USA
    Adv Exp Med Biol 603:415-24. 2007
    ..More research is required to examine the molecular mechanisms of vaccine rded by surface protein antigens and to decipher the host mechanisms responsible for vaccine success...
  69. pmc Flea-borne transmission model to evaluate vaccine efficacy against naturally acquired bubonic plague
    Clayton O Jarrett
    Laboratory of Human Bacterial Pathogenesis, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana 59840, USA
    Infect Immun 72:2052-6. 2004
    ..The model provides a means to directly assess the efficacy of new vaccines to prevent naturally acquired bubonic plague and to study events at the vector-host interface that lead to dissemination and disease...
  70. ncbi [Construction of variants of Yersinia pestis EV76 (RIEG line) vaccine strain differing in antibiotic resistance spectra with stage-by-stage transduction of R-transposons]
    A S Cherniavskaia
    Antibiot Khimioter 50:13-7. 2005
    ....
  71. pmc Intraspecific diversity of Yersinia pestis
    Andrey P Anisimov
    Department of Infectious Diseases, State Research Center for Applied Microbiology, 142279 Obolensk, Serpukhov District, Moscow Region, Russia
    Clin Microbiol Rev 17:434-64. 2004
    ..pestis strains based on genetic and phenotypic variation and show that there is a high level of diversity in these strains not reflected by ones obtained from sylvatic areas and patients in the Americas...
  72. pmc Protection of black-tailed prairie dogs (Cynomys ludovicianus) against plague after voluntary consumption of baits containing recombinant raccoon poxvirus vaccine
    Jordan S Mencher
    Wildlife Science Group, University of Washington, Seattle, Washington, USA
    Infect Immun 72:5502-5. 2004
    ..Antibody titers against Y. pestis F1 antigen increased significantly (P < 0.01) in vaccinees, and their survival was significantly higher upon challenge with Y. pestis than that of negative controls (P < 0.01)...
  73. ncbi Stat 4 but not Stat 6 mediated immune mechanisms are essential in protection against plague
    Stephen J Elvin
    Defence Science and Technology Laboratories, Porton Dowpuid_15458778">Microb Pathog 37:177-84. 2004
    ..It appears therefore that type 1 immune mechanisms, activated following Stat 4 phosphorylation, are essential in protection against plague...
  74. ncbi A plague upon the phagocytes
    Frank R Deleo
    Nat Med 11:927-8. 2005
  75. ncbi Plant-made subunit vaccine against pneumonic and bubonic plague is orally immunogenic in mice
    M Lucrecia Alvarez
    Center for Infectious Diseases and Vaccinology CIDV, The Biodesign Institute at Arizona State University, 1001 South McAllister Avenue, Tempe, AZ 85287 4501, USA
    Vaccine 24:2477-90. 2006
    ..We developed a novel production and delivery system for a plague vaccine of a Y. pestis F1-V antigen fusion protein expressed in tomato...
  76. pmc Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis
    Anna N Honko
    Department of Microbiology and Immunology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, North Carolina 27157, USA
    Infect Immun 74:1113-20. 2006
    ..immunity, we evaluated the efficacy of recombinant Salmonella flagellin as an adjuvant in an acellular plague vaccine. Mice immunized intranasally or intratracheally with the F1 antigen of Yersinia pestis and flagellin exhibited ..
  77. ncbi An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge
    Amy Palin
    Department of Pathology, Yale University School of Medicine, 310 Cedar Street LH 315, New Haven, CT 06510, USA
    Vaccine 25:741-50. 2007
    ..This VSV-based vaccine vector system has potential as a plague vaccine protecting against virulent strains lacking the F1 protein.
  78. ncbi Deadly plague versus mild-mannered TLR4
    Roman Dziarski
    Nat Immunol 7:1017-9. 2006
  79. ncbi Protection against plague following immunisation with microencapsulated V antigen is reduced by co-encapsulation with IFN-gamma or IL-4, but not IL-6
    K F Griffin
    Dstl Biomedical Sciences, Porton Down, Salisbury, SP4 0JQ, Wiltshire, UK
    Vaccine 20:3650-7. 2002
    ..pestis strain GB; however protective efficacy was impaired by co-encapsulating either IFN-gamma or IL-4 with rV...
  80. ncbi Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles
    Leenu Sabhnani
    Department of Biochemistry, All India Institute of Medical Sciences, New Delhi 110029, India
    FEMS Immunol Med Microbiol 38:215-29. 2003
    ..Newer methods of antigen delivery coupled with adjuvant offer an alternative approach toward a plague vaccine. In order to develop a new generation vaccine against plague, we chose an immunodominant, outer membrane ..
  81. ncbi Co-immunisation with a plasmid DNA cocktail primes mice against anthrax and plague
    E D Williamson
    Defence Science and Technology Laboratory, Porton Down, Salisbury, Wiltshire SP4 OJQ, UK
    Vaccine 20:2933-41. 2002
    ..pestis compared with priming only with plasmid DNA encoding the V antigen and boosting with rV. This enhancement may be due to the effect of CpG motifs known to be present in the plasmid DNA construct encoding PA...
  82. ncbi Vaccination with plasmid DNA expressing the Yersinia pestis capsular protein F1 protects mice against plague
    Haim Grosfeld
    Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, P O Box 19, Ness Ziona, Israel 74100
    Adv Exp Med Biol 529:423-4. 2003
  83. pmc Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen
    Haim Grosfeld
    Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona 74100, Israel
    Infect Immun 71:374-83. 2003
    ..Taken together, these observations indicate that a tailored genetic vaccine based on a bacterial protein can be used to confer protection against plague in mice without resorting to regimens involving the use of purified proteins...
  84. ncbi Immunological characterisation of sub-units of the Yersinia type III secretion apparatus
    James Hill
    Swedish Defence Research Agency, FOI, NBC Defence, 901 82 Umeå, Sweden
    Adv Exp Med Biol 529:415-7. 2003
  85. ncbi Outbreak of duck plague (duck herpesvirus enteritis) in numerous species of captive ducks and geese in temporal conjunction with enforced biosecurity (in-house keeping) due to the threat of avian influenza A virus of the subtype Asia H5N1
    E F Kaleta
    Klinik fur Vogel, Reptilien, Amphibien und Fische, Justus Liebig Universitat Giessen, Frankfurter Strasse 91 93, 35392 Giessen
    Dtsch Tierarztl Wochenschr 114:3-11. 2007
    ..The remaining healthy appearing birds were subcutaneously vaccinated with a modified live duck plague vaccine (Intervet, Boxmeer, NL) that stopped losses and resulted in seroconversion in most of the vaccinated birds.
  86. pmc Immunization of mice with YscF provides protection from Yersinia pestis infections
    Jyl S Matson
    Department of Microbiology and Immunology, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND 58202, USA
    BMC Microbiol 5:38. 2005
    ..pestis strains and could lead to a high rate of undesired side effects in vaccinated populations. For these reasons, the use of other antigens in a plague vaccine formulation may be advantageous.
  87. ncbi Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague
    S Welkos
    Division of Bacteriology, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702 5011, USA
    Vaccine 20:2206-14. 2002
    The current human plague vaccine, a killed Yersinia pestis whole-cell preparation, does not protect against aerosol challenge and is reactogenic and antigenically undefined. Live attenuated Y...
  88. pmc A surface-focused biotinylation procedure identifies the Yersinia pestis catalase KatY as a membrane-associated but non-surface-located protein
    Tanya Myers-Morales
    Did_PMC2074897">..be exposed to the surface and might be a candidate for evaluation as a protective antigen for an improved plague vaccine. KatY was obtained only in the total membrane fraction, and stachyose greatly reduced its biotinylation as ..
  89. ncbi Small protective fragments of the Yersinia pestis V antigen
    Claire Vernazza
    Defence Science and Technology Laboratory, Porton Down, Salisbury, Wiltshire, SP4 0JQ, UK
    Vaccine 27:2775-80. 2009
    ..pestis as a bioweapon fuel the need for efficacious vaccines. The most recent plague vaccine is a killed whole cell preparation that is expensive to manufacture and its side effects are common...
  90. ncbi Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis
    G Gupta
    Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
    Scand J Immunol 71:186-98. 2010
    ..In present study, microencapsulated B-T constructs after intranasal immunization generated systemic as well as mucosal immune response in all three sites, which offers an alternative approach for plague vaccine.
  91. ncbi Higher accumulation of F1-V fusion recombinant protein in plants after induction of protein body formation
    M Lucrecia Alvarez
    Center for Infectious Diseases and Vaccinology, The Biodesign Institute at Arizona State University, 1001 South McAllister Avenue, Tempe, AZ 85287 5401, USA
    Plant Mol Biol 72:75-89. 2010
    ..As a part of a project to develop a plant-made plague vaccine, we expressed our model antigen, the Yersinia pestis F1-V antigen fusion protein, with and without a fused ..
  92. pmc A Yersinia pestis guaBA mutant is attenuated in virulence and provides protection against plague in a mouse model of infection
    Petra C F Oyston
    Department of Biomedical Sciences, Defence Science and Technology Laboratory, Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom
    Microb Pathog 48:191-5. 2010
    ..pestis auxotrophic for guanine and avirulent; such a strain could serve as a live attenuated plague vaccine candidate. A Y...
  93. ncbi Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague
    Bradford S Powell
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702 1201, USA
    Biotechnol Prog 21:1490-510. 2005
    ..protection over the former licensed product, establish a foundation from which to create a robust production process, and set forth assays for the development of F1-V as the active pharmaceutical ingredient of the next plague vaccine.
  94. ncbi A Yersinia pestis YscN ATPase mutant functions as a live attenuated vaccine against bubonic plague in mice
    Joel Bozue
    Division of Bacteriology, US Army Medical Research Institute of Infectious Diseases, Ft Detrick, MD, USA
    FEMS Microbiol Lett 332:113-21. 2012
    ..Antibodies to F1 capsule but not to LcrV were detected in sera from the vaccinated mice. These preliminary results suggest a proof-of-concept for an attenuated, genetically engineered, live vaccine effective against bubonic plague...
  95. pmc Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells
    Kwang Chul Kwon
    Department of Molecular Biology and Microbiology, College of Medicine, University of Central Florida, Biomolecular Science Building, Orlando, FL 32816 2364, USA
    Adv Drug Deliv Rev 65:782-99. 2013
    ....
  96. ncbi Protection against anthrax and plague by a combined vaccine in mice and rabbits
    Jun Ren
    State Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, 20 FengTai Dongdajie Street, Beijing 100071, PR China
    Vaccine 27:7436-41. 2009
    ..2x10(5) colony-forming units (CFU) virulent B. anthracis spores. These data show that the protective efficacy was unaffected when the antigens were administered in combination...
  97. ncbi Multiple antigen peptide containing B and T cell epitopes of F1 antigen of Yersinia pestis showed enhanced Th1 iens were administered in combination...
  • R Ali
    Department of Biochemistry, All India Institute of Medical Sciences AIIMS, New Delhi 110029, India
    Scand J Immunol 77:361-71. 2013
  • ncbi Biophysical characterization and formulation of F1-V, a recombinant plague antigen
    Ajit Joseph M D'souza
    BD Technologies, 21 Davis Dr, Research Triangle Park, North Carolina 27519, USA
    J Pharm Sci 98:2592-602. 2009
    ..5, F1-V appears to populate predominantly in its monomeric state...
  • pmc In vitro and in vivo delivery of genes and proteins using the bacteriophage T4 DNA packaging machine
    Pan Tao
    Department of Biology, The Catholic University of America, Washington, DC 20064, USA
    Proc Natl Acad Sci U S A 110:5846-51. 2013
    ..Mice delivered with a single dose of F1-V plague vaccine containing both gene and protein in the T4 head elicited robust antibody and cellular immune responses.4, USA
    Proc Natl Acad Sci U S A 110:5846-51. 2013
    ..Mice delivered with a single dose of F1-V plague vaccine..
  • ncbi Live-attenuated Yersinia pestis vaccines
    Xiaoyi Wang
    State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, China
    Expert Rev Vaccines 12:677-86. 2013
    Plague caused by Yersinia pestis is one of the most dangerous infectious diseases. There is no ideal plague vaccine available for human use, but a number of licensed killed whole-cell and live-attenuated vaccines have been available in ..
  • ncbi Preclinical safety assessment of a recombinant plague vaccine (rF1V)
    Jessica L Price
    DynPort Vaccine Company LLC, A CSC Company, 64 Thomas Johnson Drive Frederick, MD 21702, USA Email
    Int J Toxicol 32:327-35. 2013
    ..The rF1V vaccine produced no apparent systemic toxicity and only transient edema and erythema at the injection site. Together these results indicated a favorable safety profile for rF1V and supported its use in a Phase 1 clinical trial. ..
  • Research Grants23

    1. Identification of New Antigens for a Plague Vaccine
      Ashok K Chopra; Fiscal Year: 2013
      ..Although immunization of humans with plague vaccine will discourage the use of Y. pestis as a bioweapon, currently there is no vaccine against plague...
    2. Cell-mediated protection against pneumonic plague
      Jr Shiuan Lin; Fiscal Year: 2013
      ..Thus, plague vaccine researchers have devoted little attention to cellular immunity...
    3. Evaluation of Ail as a protective immunogen for plague
      Eric S Krukonis; Fiscal Year: 2012
      ..There is currently no licensed plague vaccine in the U.S...
    4. Multivalent Plague, Anthrax Vaccines Using Bacteriophage T4 Display
      Venigalla B Rao; Fiscal Year: 2013
      ..genetic, structural, and aerosol challenge expertise, strategies are designed to develop a novel trivalent T4-plague vaccine comprised of three Yersinia Ags, the capsular Ag, Caf1, the low calcium response V Ag, LcrV, and the Yersinia ..
    5. The role of LPS-TLR4 signaling in live vaccine-induced protective responses
      Egil Lien; Fiscal Year: 2013
      ..Currently there is no available licensed plague vaccine, and exploratory vaccines have variable ability to protect against pneumonic disease, the form expected after ..
    6. Development of Enabling Vector/Antigen Expression Technology for an Orally-Delive
      B Kim Lee Sim; Fiscal Year: 2013
      ..vaccination schedule (6 doses over 18 months) and has concerns over adverse effects;and 3) the lack of a plague vaccine licensed in the United States...
    7. Improved plague vaccine by targeting dendritic cell subsets
      Yoonkyung Do; Fiscal Year: 2010
      ..Therefore, developing an effective plague vaccine, the goal of this proposal, is relevant to public health.
    8. Multi-gene Subunit Vaccine Platform Against Y. pestis
      Shan Lu; Fiscal Year: 2011
      ..Our proposal was developed based on our recent progress in plague vaccine studies which includes 1...
    9. Evaluation and Production of a Multivalent Adenoviral Plague Vaccine
      ERIC ROTHE; Fiscal Year: 2013
      ..The plague vaccine project was selected in response to the growing concern surrounding the organism's possible use in a ..
    10. Role of Yersinia pestis Ail in Yop delivery and plague
      Eric S Krukonis; Fiscal Year: 2012
      ..pestis surface protein Ail with host cells. This critical interaction is required for plague virulence and characterizing this interaction may lead to development of anti-plague therapeutics and/or an effective plague vaccine.
    11. Development, Production and Evaluation of a Multivalent Adenoviral Plague Vaccine
      CHRIS LENTZ; Fiscal Year: 2009
      ..and Introgen Therapeutics, Inc. The plague vaccine project was selected in response to the growing concern surrounding the organism's use in a potential ..
    12. Alternative endpoints for plague challenge models
      Richard Frothingham; Fiscal Year: 2005
      Yersinia pestis causes human and animal plague. Plague vaccine research has increasing importance since Y. pestis is a potential bioterrorism agent. Published Y. pestis vaccine studies use mortality as the primary endpoint...
    13. Mucosal modified vaccinina Ankara-based plaque vaccines
      DAN STINCHCOMB; Fiscal Year: 2007
      ..goal is to optimize antigen expression by recombinant MVA and develop a highly safe mucosal MVA-based plague vaccine that protects against aerosol exposure to both Y. pestis and smallpox virus. The specific aims are as follows...
    14. Development of ProtollinTM Plague Vaccine
      George Lowell; Fiscal Year: 2004
      The aim of this work is to develop a nasal sub-unit Plague vaccine using the recombinant Plague antigen F1V formulated with ProteosomeTM-based ProtollinTM adjuvant to provide protection against the bioterror threat posed by aerosol-..
    15. Plague vaccine candidates by a functional genomic screen
      Kathryn Sykes; Fiscal Year: 2002
      ..abstract_text> ..
    16. Multi-gene plague vaccine with expanded protection
      Shan Lu; Fiscal Year: 2004
      The overall objective of this application is to rapidly develop much needed alternative plague vaccine candidate formulations based on our recent discovery that a modified Y...
    17. Surface proteins in pneumonic plague
      SUSAN STRALEY; Fiscal Year: 2005
      ..These studies will provide the technical base for a more detailed screen for new plague vaccine candidates...
    18. LcrV Plague Vaccine with Altered Immune Modulatory Properties
      Olaf Schneewind; Fiscal Year: 2008
      ..the associated suppression of host defense mechanisms may preclude the use of full length LcrV as a human plague vaccine. Herein we show that short deletions within LcrV can reduce its immune modulatory properties...
    19. Roles for coagulation in immunity
      STEPHEN SMILEY; Fiscal Year: 2005
      ..Deciphering those mechanisms may lead to improved vaccines and/or treatments for pathologies characterized by fibrin deposition, including autoimmunity, allograft rejection, cancer and septic shock. ..
    20. Priming CD4+ T cells to protect against pneumonic plague
      STEPHEN SMILEY; Fiscal Year: 2004
      ..Our long-term goals are to use that information to develop effective pneuinonic plague vaccines. ..
    21. Cell-mediated protection against pneumonic plague
      STEPHEN SMILEY; Fiscal Year: 2008
      ..Thus, plague vaccine researchers have devoted little attention to cellular immunity...
    22. Respiratory Immunity Against Agents of Bioterrorism
      STEVEN MIZEL; Fiscal Year: 2008
      ....
    23. Activation of inflammatory cells by flagellin
      STEVEN MIZEL; Fiscal Year: 2006
      ..Furthermore, the proposed studies should also provide insights into the factors that regulate TLR signaling and allow for complex patterns of host cell response. ..